menu
    • menu
    [{"orgOrder":0,"company":"ClearPoint Neuro","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Gene-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"ClearPoint Neuro","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"ClearPoint Neuro \/ UCB Pharma S.A","highestDevelopmentStatusID":"3","companyTruncated":"ClearPoint Neuro \/ UCB Pharma S.A"},{"orgOrder":0,"company":"ClearPoint Neuro","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Eladocagene Exuparvovec","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ClearPoint Neuro","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ClearPoint Neuro \/ ClearPoint Neuro","highestDevelopmentStatusID":"10","companyTruncated":"ClearPoint Neuro \/ ClearPoint Neuro"}]

    Find Clinical Drug Pipeline Developments & Deals by ClearPoint Neuro

    Menu

    ClearPoint Neuro

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ClearPoint Neuro

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ClearPoint Neuro

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eladocagene Exuparvovec

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : PTC Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            ClearPoint Congratulates PTC Therapeutics On Upstaza™ BLA Submission

                            Details : Upstaza (eladocagene exuparvovec) is a gene therapy expressing the human aromatic L-amino acid decarboxylase enzyme, evaluated for AADC deficiency treatment.

                            Brand Name : Upstaza

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 19, 2024

                            Lead Product(s) : Eladocagene Exuparvovec

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : PTC Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ClearPoint Neuro

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            ClearPoint Neuro

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gene-based Therapy

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : UCB Pharma S.A

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

                            Details : Under the terms of the license agreement, UCB will utilize ClearPoint Neuro’s proprietary technology and services in connection with the development and commercialization of UCB’s gene therapy products.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 24, 2023

                            Lead Product(s) : Gene-based Therapy

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : UCB Pharma S.A

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth